A Phase 1/2 interventional study of KDTV001 in HPV (Human Papillomavirus)-Associated, HPV 16/18 and HPV 52, sponsored by Wuhan KadGeno Biotechnology Co., Ltd. Recruiting at 2 sites in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Wuhan KadGeno Biotechnology Co., Ltd · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in Papillomavirus Infections with a site in China — 27 open to participants now, 40 under way, 10 of them phase 3. Papillomavirus Infections · China.
Among the 69 studies in Papillomavirus Infections with a site in China, this one is the 26th largest by planned enrollment of the 45 interventional ones that give a count, is one of 8 that started in 2026, is one of 3 in phase 1/2, reaches primary completion later than 24 of the 39 other live ones, and was the 67th registered.
582 studies on the registry are indexed under Papillomavirus Infections; 134 are open to participants now.
Browse Papillomavirus Infections studies →27 of the 69 studies in Papillomavirus Infections with a site in China are open now. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in China
Ages 10–45 · Women only · Healthy volunteers
Beijing Xunsheng Biomedical Research Co., Ltd. · Sites in China
Ages 18–64 · Women only
Shanghai Mianyi Biopharmaceutical Co., Ltd. · Sites in China
Ages 18–55 · Women only
Second Affiliated Hospital, Zhejiang University, School of Medicine · Sites in China
Ages 25–65 · Women only · Healthy volunteers
The First Hospital of Jilin University · Sites in China
Ages 26–65 · Women only
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 88 Papillomavirus Infections studies recruiting now, 39 (44%) set no upper age limit and 44 (50%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 10 · Phase 3 18 · Phase 4 3
First in 2005; this study’s year is marked. 8 started in 2026.
This study's planned enrollment of 304 is above the median of 227 across 405 interventional studies indexed under Papillomavirus Infections.
Median enrollment 480 across the 45 interventional studies, 2,600 across the 24 observational. Of the 18 that completed or were terminated, 5 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 69 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Wuhan KadGeno Biotechnology Co., Ltd as lead sponsor.
Wuhan KadGeno Biotechnology Co., Ltd has 1 study filed under Papillomavirus Infections — fewer than ten, so there is no comparison to draw.
6 of the studies in Papillomavirus Infections with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07833852Shanghai Zerun Biotechnology Co.,LtdLong-Term Immune Persistence After Bivalent HPV Vaccination in Females From Study 311-HPV-1005 | 2026-12 |
| NCT06137352Fujian Maternity and Child Health HospitalTwo Domestic HPV Vaccines and Imported HPV Vaccines in Women Aged 13-14 Years Study on Immunogenicity | 2026-12-31 |
| NCT07820241Shanghai Zerun Biotechnology Co.,LtdLong-term Immune Persistence of a Bivalent HPV Vaccine in Females From Study 311-HPV-1004 | 2027-04 |
| NCT05371353Shanghai Bovax Biotechnology Co., Ltd.Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine | 2027-05 |
| NCT07942779Beijing Xunsheng Biomedical Research Co., Ltd.AVL-102 for the Treatment of HPV 16/18/52/58-Related High-Grade Lesions | 2027-07-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 69 studies in Papillomavirus Infections with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
KDTV001 Injection is a non-replicating adenovirus serotype 5 (Ad5)-based therapeutic HPV vaccine developed by Wuhan KadGeno Biotechnology Co., Ltd. It utilizes an engineered adenoviral vector expressing the HPV16/18/52 E6/E7 fusion protein under CMV promoter control, designed to inducing a robust cellular immune response that eradicates HPV-related lesions.
This is a Phase I, multicenter, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, immunogenicity, and preliminary efficacy of KDTV001 Injection in participants with HPV types 16, and/or 18, and/or 52-associated cervical HSIL.
The study consists of three parts: dose escalation, an immunogenicity expansion cohort (Phase 1), and a dose expansion phase (Phase 2). In Phase 1a, 3+3 dose escalation of KDTV001 Injection will be conducted separately for IM and IC administration, with two ascending dose levels evaluated for each route. During the dose-escalation phase, if a dose cohort is assessed as safe by SRC, an immunogenicity expansion of 10-20 participants may be conducted. Based on Phase 1 safety and immunogenicity data, 1-2 dose levels will be selected for Phase 2 dose expansion for both IC and IM. In the Phase 2 dose-expansion phase, each dose cohort will enroll 30-50 participants. Both phases will consist of a screening period, a treatment and safety follow-up period, an end of study visit (EOS) and a long-term follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
a as defined by spontaneous amenorrhea for more than 12 months; b Surgically sterile due to absence of ovaries or due to a bilateral tubal ligation/occlusion performed more than 12 months prior to screening; c Women of Child Bearing Potential () must have a negative serum pregnancy test during the screening period; participants must agree to use reliable methods (barrier methods or abstinence) with their partners during the study and for at least 12 months after the last dose of product.
- Be willing to participate in this study and provide a signed form prior to participating in the trial.
Exclusion Criteria:
Have a history of severe cardiovascular or cerebrovascular diseases, including but not limited to:
Have any of the following serum virology findings:
Active infection defined as:
HBsAg positive AND HBV-DNA >500 IU/mL or above institutional detection limit if higher than standard threshold (only when the lower limit of detection threshold of the clinical trial institution is higher than 500 IU/mL)
Currently receiving OR have received following doses of systemic therapy prior to the first administration of the product:
Note: Topical, ocular, intra-articular, nasal, or inhaled corticosteroids are permitted.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
KDTV001:1 × 10\^11 VP, IM, W0, W4, W12
Drug: KDTV001
KDTV001: 3 × 10\^11 VP, IM, W0, W4, W12
Drug: KDTV001
KDTV001: 1 × 10\^10 VP, IC, W0, W4, W12
Drug: KDTV001
KDTV001: 3 × 10\^10 VP, IC, W0, W4, W12
Drug: KDTV001
KDTV001 Injection is a non-replicating adenovirus serotype 5 (Ad5)-based therapeutic HPV vaccine developed by Wuhan KadGeno Biotechnology Co., Ltd. It utilizes an engineered adenoviral vector expressing the HPV16/18/52 E6/E7 fusion protein under CMV promoter control, designed to inducing a robust cellular immune response that eradicates HPV-related lesions.
Phase 1: Incidence of Any Adverse Events (AEs), Treatment related AEs (TRAEs) and Serious Adverse Events (SAEs) Following Investigational Treatment for the Duration of the Study
Percentage of participants with AE/TRAE/SAE in FAS population
Time frame: From enrollment to 2 years after the first dose.
Phase 2: Percentage of Participants With No Evidence of Cervical HSIL on Histology and No Evidence of HPV-16 and HPV-18 and HPV-52 in Cervical Samples
Participants with no histologic (i.e., biopsies or excisional treatment) evidence of cervical HSIL, no evidence of HPV-16 and HPV-18 and HPV-52 at the Week 36 time frame, and participants in which excision or biopsy sample was not obtained between the initial dose up to Week 36 were considered to be responders. No evidence of HSIL was defined by histology as negative, squamous atypia, or low-grade intraepithelial lesion (LSIL). HPV testing will be performed using the cobas® assay and a second assay kit manufactured in China to identify HPV 52.
Time frame: From enrollment to 36 weeks after the first dose.
Phase 1: HPV clearance rates after dosing;
Incidence of Participants with no evidence of HPV-16 and HPV-18 and HPV-52 at Week 12, 24, and 36, and Week 52, 78, and 104 if the participants do not have excisional treatment. HPV testing will be performed using the cobas® assay and a second assay kit manufactured in China to identify HPV 52.
Time frame: From enrollment to 104 weeks after the first dose.
Phase 2: The immunogenicity of KDTV001 injection;
Immunogenicity within 52 weeks after the first dose: cellular immune responses against E6/E7 of HPV16/18/52, including enzyme-linked immunospot (ELISPOT) assay and flow cytometry, etc.
Time frame: From enrollment to 52 weeks after the first dose.
Companion biomarkers of KDTV001
* HPV integration; * Patient HLA typing; * p16, HPV E6/E7 and Ki67 gene expression analysis as well as immune infiltration analysis, etc. of cervical tissues; * Cervical gene methylation level; * Cell-free Human Papillomavirus DNA (cfDNA-HPV), peripheral blood immune cell subsets, and related antibody production (e.g. peripheral blood antibodies to HPV16/18/52 E6/E7 and viral vector (Ad5)).
Time frame: From enrollment to 52 weeks after the first dose.
Started Jan 2026 (actual). Primary completion is estimated for Nov 2027, 22 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.